Aspecte ale tratamentului anemiei renale cu eritropoietină

Negru-Mihalache, Rodica; Mastak, Dumitru; Vasilev, Andrei; Axenti, Alin

dc.contributor.author	Negru-Mihalache, Rodica
dc.contributor.author	Mastak, Dumitru
dc.contributor.author	Vasilev, Andrei
dc.contributor.author	Axenti, Alin
dc.date.accessioned	2022-05-25T08:02:57Z
dc.date.available	2022-05-25T08:02:57Z
dc.date.issued	2002
dc.identifier.citation	NEGRU-MIHALACHE, Rodica, MASTAK, D., VASILEV, A., AXENTI, A. Aspecte ale tratamentului anemiei renale cu eritropoietină. In: Conferința III de Urologie, Conferința II de Nefrologie, Dializă și Transplant Renal din Republica Moldova, 30-31 octombrie 2002, Chișinău: culegere de lucrări. Chișinău, 2002, pp. 184-186.
dc.identifier.uri	http://repository.usmf.md/handle/20.500.12710/20741
dc.description.abstract	Summary. Anaemia is a consistent finding in chronic renal disease, affecting up to 90% of patients, and the central role of anaemia in the development of cardiovascular dysfunction is now well established. Although iron deficiency is probably the most important factor affecting response to recombinant erytropoietin (Epo, epoetin), other factors are of significance, including dialysis adequacy. Additionally, water treatment and distribution, sterilizants and the quality of the dialysate in terms of trace elements (particularly chloramine) are of importance in relation to erythropoiesis inhibition.	en_US
dc.language.iso	ro	en_US
dc.publisher	Societatea Urologilor din Republica Moldova	en_US
dc.relation.ispartof	Culegere de lucrări Conferința 3-a de Urologie, Conferința 2-a de Nefrologie: Dializa și Transplant Renal din Republica Moldova (30 - 31 octombie 2002)	en_US
dc.title	Aspecte ale tratamentului anemiei renale cu eritropoietină	en_US
dc.type	Article	en_US